Our top pick for
Beginners
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
How to buy Zymeworks stock | $41.61
Own Zymeworks stock in just a few minutes.
Zymeworks Inc is a biotechnology business based in the US. Zymeworks shares (ZYME) are listed on the NYSE and all prices are listed in US Dollars. Zymeworks employs 325 staff and has a trailing 12-month revenue of around USD$25.1 million.
How to buy shares in Zymeworks
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Zymeworks. Find the stock by name or ticker symbol: ZYME. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zymeworks reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$41.61, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Zymeworks, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Zymeworks. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Zymeworks share price
Use our graph to track the performance of ZYME stocks over time.Zymeworks shares at a glance
Information last updated 2020-11-30.
| Latest market close | USD$41.61 |
|---|---|
| 52-week range | USD$20.33 - USD$53.15 |
| 50-day moving average | USD$43.0238 |
| 200-day moving average | USD$37.6888 |
| Wall St. target price | USD$24.88 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.63 |
Buy Zymeworks shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Zymeworks stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Zymeworks price performance over time
Historical closes compared with the close of $41.61 from 2020-11-16
| 1 week (2020-11-25) | -14.29% |
|---|---|
| 1 month (2020-11-06) | 0.14% |
| 3 months (2020-09-04) | 31.26% |
| 6 months (2020-06-05) | 13.69% |
| 1 year (2019-12-05) | -0.74% |
|---|---|
| 2 years (2018-12-04) | 224.82% |
| 3 years (2017-12-05) | 390.82% |
| 5 years (2015-12-02) | N/A |
Zymeworks financials
| Revenue TTM | USD$25.1 million |
|---|---|
| Gross profit TTM | USD$-86,356,000 |
| Return on assets TTM | -28.78% |
| Return on equity TTM | -57.94% |
| Profit margin | 0% |
| Book value | $9.44 |
| Market capitalisation | USD$2.4 billion |
TTM: trailing 12 months
Shorting Zymeworks shares
There are currently 1.3 million Zymeworks shares held short by investors – that's known as Zymeworks's "short interest". This figure is 29.9% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Zymeworks shares can be evaluated.
Zymeworks's "short interest ratio" (SIR)
Zymeworks's "short interest ratio" (SIR) is the quantity of Zymeworks shares currently shorted divided by the average quantity of Zymeworks shares traded daily (recently around 269386.96537678). Zymeworks's SIR currently stands at 4.91. In other words for every 100,000 Zymeworks shares traded daily on the market, roughly 4910 shares are currently held short.
However Zymeworks's short interest can also be evaluated against the total number of Zymeworks shares, or, against the total number of tradable Zymeworks shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zymeworks's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Zymeworks shares in existence, roughly 30 shares are currently held short) or 0.0291% of the tradable shares (for every 100,000 tradable Zymeworks shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zymeworks.
Find out more about how you can short Zymeworks stock.
Zymeworks share dividends
We're not expecting Zymeworks to pay a dividend over the next 12 months.
Zymeworks share price volatility
Over the last 12 months, Zymeworks's shares have ranged in value from as little as $20.33 up to $53.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zymeworks's is 0.8202. This would suggest that Zymeworks's shares are less volatile than average (for this exchange).
Zymeworks overview
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Frequently asked questions
More guides on Finder
-
How to buy Hertz Global stock | $2.27
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
-
How to buy Helen of Troy stock | $211.57
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
-
How to buy Hawaiian Electric Industries stock | $35.92
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
-
How to buy Glaukos Corporation stock | $70.23
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
-
How to buy Eyenovia stock | $3.87
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
-
How to buy Exact Sciences Corporation stock | $132.87
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
-
How to buy Evofem Biosciences stock | $2.22
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
-
How to buy Everspin Technologies stock | $5.3
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
-
How to buy Equinor ASA stock | $16.73
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
-
How to buy Electrameccanica Vehicles stock | $6.85
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
Ask an Expert